In a recent presentation at SXSW, Jeffrey Lieberman, MD, spoke about the potential of mindbending drugs such as psychedelics and cannabis in the context of physician leadership. While the level of interest in these substances was high, Lieberman emphasized the importance of responsible use and scientific research.

Jeffrey A. Lieberman, MD, is the Lawrence C. Kolb Professor of Psychiatry at Columbia University Medical Center. His work has advanced the understanding of the natural history and pathophysiology of schizophrenia and the pharmacology and clinical effectiveness of antipsychotic drugs.

He is a member of numerous scientific organizations, including the National Academy of Sciences Institute of Medicine. He has authored more than 500 papers and articles published in the scientific literature and written and/or edited ten books on mental illness, psychopharmacology, and psychiatry. Lieberman served as president of the American Psychiatric Association (APA) from 2013 to 2014.

During this podcast interview with host, Mike Sacopulos, Lieberman discussed the potential benefits and risks of using mindbending drugs in a clinical setting. He emphasized the need for rigorous scientific research and noted that while these substances may have therapeutic potential, they must be used with caution and under the guidance of trained medical professionals.

As the field of psychiatry continues to evolve, it will be important for physicians to approach these substances with a balanced and informed perspective and to fully understand the effects of these substances on the human brain and behavior.

Learn more about the American Association for Physician Leadership at www.physicianleaders.org